Based on the VanEck Pharmaceutical ETF stock forecast from 0 analysts, the average analyst target price for VanEck Pharmaceutical ETF is not available over the next 12 months. VanEck Pharmaceutical ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of VanEck Pharmaceutical ETF is Bullish , which is based on 8 positive signals and 2 negative signals. At the last closing, VanEck Pharmaceutical ETF’s stock price was USD 86.80. VanEck Pharmaceutical ETF’s stock price has changed by +1.95% over the past week, -3.47% over the past month and +10.80% over the last year.
No recent analyst target price found for VanEck Pharmaceutical ETF
No recent average analyst rating found for VanEck Pharmaceutical ETF
Company Overview VanEck Pharmaceutical ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. Read Less
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitali...Read More
Frequently Asked Questions About VanEck Pharmaceutical ETF (PPH) Stock
Stock Target Advisor's fundamental analysis for VanEck Pharmaceutical ETF's stock is Bullish .
PPH stock's dividend yield is 1.91%.
Our analysis grades PPH stock's dividend yield at A+. This means that PPH stock's dividend yield is above 100% of the stocks in the Health sector in the NSD exchange.
Based on this PPH may be a good dividend stock for its sector.
Unfortunately we do not have enough data on PPH's stock to indicate what its average analyst target is.
PPH stock's Price/Earning ratio is 14.65.
Our analysis grades PPH stock's Price / Earning ratio at B. This means that PPH stock's Price/Earning ratio is above 17% of the stocks in the Health sector in the NSD exchange.
Based on this PPH may be undervalued for its sector.
The last closing price of PPH's stock was USD 86.80.
The most recent market capitalization for PPH is USD 0.51B.
Unfortunately we do not have enough analyst data on PPH's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains VanEck Pharmaceutical ETF's stock.
As per our most recent records VanEck Pharmaceutical ETF has 0 Employees.
VanEck Pharmaceutical ETF's registered address is Motion Building, Amsterdam, Netherlands, 1043.
You can get more information about it from VanEck Pharmaceutical ETF's website at http://www.vaneck.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
